Prospera Financial Services Inc decreased its holdings in shares of Amgen, Inc. (NASDAQ:AMGN) by 23.4% in the fourth quarter, HoldingsChannel reports. The institutional investor owned 2,221 shares of the medical research company’s stock after selling 679 shares during the quarter. Prospera Financial Services Inc’s holdings in Amgen were worth $394,000 at the end of the most recent reporting period.
Other institutional investors have also added to or reduced their stakes in the company. Janus Henderson Group PLC boosted its position in shares of Amgen by 3,664.7% during the 2nd quarter. Janus Henderson Group PLC now owns 3,699,351 shares of the medical research company’s stock valued at $637,139,000 after acquiring an additional 3,601,087 shares during the last quarter. FMR LLC boosted its position in shares of Amgen by 4.8% during the 2nd quarter. FMR LLC now owns 56,999,572 shares of the medical research company’s stock valued at $9,817,037,000 after acquiring an additional 2,587,041 shares during the last quarter. Renaissance Technologies LLC boosted its position in shares of Amgen by 40.9% during the 2nd quarter. Renaissance Technologies LLC now owns 3,400,145 shares of the medical research company’s stock valued at $585,607,000 after acquiring an additional 986,700 shares during the last quarter. BlackRock Inc. boosted its position in shares of Amgen by 1.9% during the 2nd quarter. BlackRock Inc. now owns 49,451,203 shares of the medical research company’s stock valued at $8,516,980,000 after acquiring an additional 909,689 shares during the last quarter. Finally, Nordea Investment Management AB boosted its position in shares of Amgen by 12.9% during the 2nd quarter. Nordea Investment Management AB now owns 7,040,599 shares of the medical research company’s stock valued at $1,212,602,000 after acquiring an additional 806,119 shares during the last quarter. 78.03% of the stock is owned by institutional investors and hedge funds.
Shares of Amgen, Inc. (NASDAQ AMGN) opened at $183.77 on Thursday. The company has a debt-to-equity ratio of 1.35, a quick ratio of 5.17 and a current ratio of 5.49. The stock has a market cap of $133,873.25, a PE ratio of 14.77, a price-to-earnings-growth ratio of 2.22 and a beta of 1.42. Amgen, Inc. has a one year low of $152.16 and a one year high of $201.23.
Amgen announced that its board has authorized a share buyback program on Thursday, February 1st that permits the company to buyback $10.00 billion in outstanding shares. This buyback authorization permits the medical research company to purchase shares of its stock through open market purchases. Stock buyback programs are usually a sign that the company’s board believes its shares are undervalued.
The firm also recently declared a quarterly dividend, which will be paid on Thursday, March 8th. Shareholders of record on Thursday, February 15th will be paid a dividend of $1.32 per share. The ex-dividend date of this dividend is Wednesday, February 14th. This is a positive change from Amgen’s previous quarterly dividend of $1.15. This represents a $5.28 dividend on an annualized basis and a yield of 2.87%. Amgen’s dividend payout ratio is 205.45%.
In other Amgen news, EVP Sean E. Harper sold 1,525 shares of the business’s stock in a transaction dated Tuesday, December 12th. The shares were sold at an average price of $176.83, for a total transaction of $269,665.75. Following the sale, the executive vice president now directly owns 56,106 shares in the company, valued at $9,921,223.98. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Insiders have sold 4,575 shares of company stock worth $818,361 over the last quarter. Insiders own 0.19% of the company’s stock.
Several research analysts have recently weighed in on AMGN shares. Piper Jaffray Companies reissued a “buy” rating on shares of Amgen in a research report on Tuesday, January 2nd. Mizuho set a $192.00 target price on shares of Amgen and gave the company a “buy” rating in a research report on Thursday, December 28th. Goldman Sachs Group cut shares of Amgen from a “conviction-buy” rating to a “buy” rating in a research report on Friday, December 15th. Oppenheimer set a $205.00 target price on shares of Amgen and gave the company a “buy” rating in a research report on Tuesday, December 12th. Finally, Cann reaffirmed a “buy” rating and issued a $205.00 target price on shares of Amgen in a research report on Thursday, November 30th. Sixteen equities research analysts have rated the stock with a hold rating and eleven have assigned a buy rating to the stock. Amgen currently has a consensus rating of “Hold” and an average price target of $191.72.
ILLEGAL ACTIVITY WARNING: “Prospera Financial Services Inc Reduces Stake in Amgen, Inc. (AMGN)” was first posted by Ticker Report and is the property of of Ticker Report. If you are viewing this piece of content on another domain, it was illegally copied and republished in violation of US & international copyright laws. The original version of this piece of content can be viewed at https://www.tickerreport.com/banking-finance/3229968/prospera-financial-services-inc-reduces-stake-in-amgen-inc-amgn.html.
Amgen Inc is a biotechnology company. The Company discovers, develops, manufactures and delivers various human therapeutics. It operates in human therapeutics segment. Its marketed products portfolio includes Neulasta (pegfilgrastim); erythropoiesis-stimulating agents (ESAs), such as Aranesp (darbepoetin alfa) and EPOGEN (epoetin alfa); Sensipar/Mimpara (cinacalcet); XGEVA (denosumab); Prolia (denosumab); NEUPOGEN (filgrastim), and other marketed products, such as KYPROLIS (carfilzomib), Vectibix (panitumumab), Nplate (romiplostim), Repatha (evolocumab), BLINCYTO (blinatumomab), IMLYGIC (talimogene laherparepvec) and Corlanor (ivabradine).
Want to see what other hedge funds are holding AMGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Amgen, Inc. (NASDAQ:AMGN).
Receive News & Ratings for Amgen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen and related companies with MarketBeat.com's FREE daily email newsletter.